Magenta Therapeutics, Inc.’s $100 Million Initial Public Offering

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $100 million initial public offering of common stock of Magenta…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Ambrogio Visconti

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here